scholarly journals 18F-Labeled Silicon-Based Fluoride Acceptors: Potential Opportunities for Novel Positron Emitting Radiopharmaceuticals

2014 ◽  
Vol 2014 ◽  
pp. 1-20 ◽  
Author(s):  
Vadim Bernard-Gauthier ◽  
Carmen Wängler ◽  
Esther Schirrmacher ◽  
Alexey Kostikov ◽  
Klaus Jurkschat ◽  
...  

Background.Over the recent years, radiopharmaceutical chemistry has experienced a wide variety of innovative pushes towards finding both novel and unconventional radiochemical methods to introduce fluorine-18 into radiotracers for positron emission tomography (PET). These “nonclassical” labeling methodologies based on silicon-, boron-, and aluminium-18F chemistry deviate from commonplace bonding of an [18F]fluorine atom (18F) to either an aliphatic or aromatic carbon atom. One method in particular, the silicon-fluoride-acceptor isotopic exchange (SiFA-IE) approach, invalidates a dogma in radiochemistry that has been widely accepted for many years: the inability to obtain radiopharmaceuticals of high specific activity (SA) via simple IE.Methodology.The most advantageous feature of IE labeling in general is that labeling precursor and labeled radiotracer are chemically identical, eliminating the need to separate the radiotracer from its precursor. SiFA-IE chemistry proceeds in dipolar aprotic solvents at room temperature and below, entirely avoiding the formation of radioactive side products during the IE.Scope of Review.A great plethora of different SiFA species have been reported in the literature ranging from small prosthetic groups and other compounds of low molecular weight to labeled peptides and most recently affibody molecules.Conclusions.The literature over the last years (from 2006 to 2014) shows unambiguously that SiFA-IE and other silicon-based fluoride acceptor strategies relying on18F−leaving group substitutions have the potential to become a valuable addition to radiochemistry.

2019 ◽  
Vol 107 (9-11) ◽  
pp. 1027-1031 ◽  
Author(s):  
Suzanne E. Lapi ◽  
Jonathan W. Engle

Abstract Halogen radioisotopes have a variety of physical half-lives which are suitable for probing a wide variety of pharmacokinetic processes. Compared with other radiohalogens, relatively little work has been done with radiochlorine. However, high specific activity radioisotopes of chlorine are available from low energy cyclotron production in quantities suitable for positron emission tomography (PET) and fundamental research. In particular, the sole radioisotope of chlorine which may be used for PET imaging, 34mCl, has achieved a state of development that permits imaging in clinical settings though sparse research effort has been focused on this isotope over the last 40 years. Additionally, the other longer-lived radioisotopes of chlorine will likely continue to show utility for more traditional radiotracer studies and chemistry development.


2007 ◽  
Vol 18 (6) ◽  
pp. 2085-2089 ◽  
Author(s):  
Esther Schirrmacher ◽  
Björn Wängler ◽  
Marek Cypryk ◽  
Gerrit Bradtmöller ◽  
Martin Schäfer ◽  
...  

1999 ◽  
Vol 19 (9) ◽  
pp. 956-966 ◽  
Author(s):  
Justin S. Smith ◽  
Jon-Kar Zubieta ◽  
Julie C. Price ◽  
John E. Flesher ◽  
Igal Madar ◽  
...  

The regional binding of N1′ -([11C]methyl)naltrindole (MeNTI), a selective δ-opioid antagonist, was studied in healthy human subjects with positron emission tomography (PET). After the bolus intravenous administration of high specific activity [11C]MeNTI, PET was performed over 90 minutes. Arterial plasma samples were obtained during the scanning period and assayed for the presence of radiolabeled metabolites. The data were analyzed with various kinetic (two-and three-compartment models, Patlak graphical analysis) and nonkinetic (apparent volume of distribution and activity at a late scanning time) approaches. This tracer showed irreversible binding characteristics during the scanning period used. The results of the analyses also were compared with the density and distribution of δ-opioid receptors in the human brain in vitro. Additionally, computer simulations were performed to assess the effects of changes in receptor binding and tracer transport changes on the perceived binding parameters obtained with the models. A constrained three-compartment kinetic model was demonstrated to be superior to other quantification models for the description of MeNTI kinetics and quantification of δ receptor binding in the human brain with 11C-labeled MeNTI.


Author(s):  
Sean S. Tanzey ◽  
Xia Shao ◽  
Jenelle Stauff ◽  
Janna Arteaga ◽  
Phillip Sherman ◽  
...  

Positron emission tomography (PET) imaging of Colony Stimulating Factor 1 Receptor (CSF1R) is a new strategy for quantifying both neuroinflammation and inflammation in the periphery since CSF1R is expressed on microglia. AZ683 has high affinity for CSF1R (Ki = 8 nM; IC50 = 6 nM) and >250-fold selectivity over 95 other kinases and, in this paper, we report the radiosynthesis of [11C]AZ683 and initial evaluation of its use in CSF1R PET. [11C]AZ683 was synthesized by 11C-methylation of the desmethyl precursor with [11C]MeOTf in 3.0% non-corrected activity yield (based upon [11C]MeOTf), >99% radiochemical purity and high specific activity. Preliminary PET imaging with [11C]AZ683 revealed no brain uptake in rodents and nonhuman primates suggesting that [11C]AZ683 is a poor candidate for imaging neuroinflammation, but that it could still be useful for peripheral imaging of inflammation.


1995 ◽  
Vol 10 (1) ◽  
pp. 4-13 ◽  
Author(s):  
Aymen Al-Shamkhani ◽  
Ruth Duncan

Tb monitor the fate of alginate following systemic administration, a method was developed that allowed the covalent incorporation of approximately 1 mol% tyrosinamide. The product could be radioiodinated to a high specific activity, and was subsequently stable on storage at 4°C for 30 days, with very little (c 1%) free [125I] iodide released over that period. Twenty-four hours following intravenous administration, the low molecular weight fraction (<48,000) of the injected polymer was excreted in the urine while the larger polymer fraction remained in the circulation and did not readily accumulate in any of the tissues. Almost all of the dose administered by intraperitoneal injection was transferred from the peritoneal cavity to the blood compartment within 24 h, with the low molecular weight fraction of the polymer excreted in the urine. Following subcutaneous administration, the majority (-70%) of the injected dose was retained at the site of injection at 24 h.


Development ◽  
1976 ◽  
Vol 36 (3) ◽  
pp. 555-559
Author(s):  
A. H. Wyllie ◽  
E. M. De Robertis

Tyrosinase was measured in oocytes of the recently described albino mutant (avav) of Xenopus laevis. Although these oocytes show no pigmentation and the eggs are known to contain no melanosomes, tyrosinase — which is probably the only enzyme necessary for melanin synthesis from tyrosine — was increased more than twofold relative to the wild type. Tyrosinase recovered from albino and wild type oocytes showed the same KM with respect to tyrosine, and this was not altered by previous gonadotrophin stimulation in vivo. The tyrosi-nase assay, based on [14]tyrosine incorporation into acid-insoluble products, was of greater sensitivity than previously described methods of the same type, through removal of low molecular weight material from the oocyte homogenate prior to incubation, and the use of tyrosine of high specific activity.


2012 ◽  
Vol 11 (4) ◽  
pp. 7290.2011.00051 ◽  
Author(s):  
Dipti Kakkar ◽  
Anjani K. Tiwari ◽  
Harpal Singh ◽  
Anil K. Mishra

Nuclear medicine techniques provide potential non-invasive tools for imaging infections and inflammations in the body in a precise way. These techniques are further exploited by the use of radiopharmaceuticals in conjunction with imaging tests such as scintigraphy and positron emission tomography. Improved agents for targeting infection exploit the specific accumulation of radiolabeled compounds to understand the pathophysiologic changes involved in the inflammatory process and correlate them with other chronic illnesses. In the recent past, a wide variety of radiopharmaceuticals have been developed, broadly classified as specific radiopharmaceuticals and nonspecific radiopharmaceuticals. New developments in positron emission (leveraging 18F and 18fluorodeoxyglucose) and heterocyclic/peptide chemistry and radiochemistry are resulting in unique agents with high specific activity. Various approaches to visualizing infection and inflammation are presented in this review, in an integral manner, that give a clear view of the existing radiopharmaceuticals in clinical practice and those under development.


1981 ◽  
Vol 45 (03) ◽  
pp. 214-218 ◽  
Author(s):  
D P Thomas ◽  
R E Merton ◽  
W E Lewis ◽  
T W Barrowcliffe

SummaryIn vitro and in vivo studies were carried out on a commercially prepared low molecular weight heparin fraction. By APTT assay the fraction had a specific activity of half that of unfractionated mucosal heparin, yet retained full potency by anti-Xa assay (both clotting and chromogenic substrate). When administered intravenously to human volunteers, the anti-Xa/APTT ratio remained the same as it was in vitro. However, after subcutaneous injection, the ratio increased and anti-Xa activity could not be fully neutralized ex vivo by PF4. The fraction was as effective as unfractionated heparin in preventing experimental serum-induced thrombosis, suggesting that a heparin fraction with high specific activity by anti-Factor Xa assay compared to APTT activity may be an effective drug for the prophylaxis of venous thrombosis.


1991 ◽  
Vol 34 (2) ◽  
pp. 861-863 ◽  
Author(s):  
Yu Shin Ding ◽  
Joanna S. Fowler ◽  
S. John Gatley ◽  
Stephen L. Dewey ◽  
Alfred P. Wolf ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document